Print the page
Increase font size
One Thing AI Can’t Do

One Thing AI Can’t Do

Chris Campbell

Posted August 30, 2024

Chris Campbell

This year, I’ve become a bit of a mead maniac—obsessed with brewing the perfect batch.

Making mead is like stepping back in time.

It's an ancient art, a ritual that’s been passed down through generations.

You start with simple ingredients: honey, water, and yeast. Maybe you get a little creative and add herbs.

(The Celts used heather flowers in their mead for its medicinal properties. The Vikings used meadowsweet. The Greeks? Hyssop. The list goes on.)

But the magic happens in the wait.

Mead is a slow brew.

We’re talking months, sometimes even years. You don’t rush it because you can’t. You let nature do its thing, allowing the flavors to evolve, deepen, and mature.

This deliberate process is part of what makes mead so special.

It’s what gives mead its character, its soul.

But let’s be real—few things in life need to take this long.

Some things, like saving lives, don’t get better by hiding them in a dark closet and waiting. They demand speed, precision, and urgency.

Unlike mead, which SHOULD take time, discovering and developing life-saving drugs is an area where speed matters—a lot.

Every day, every week shaved off the drug discovery process can mean the difference between life and death for countless people.

For decades, drug discovery has been this slow, grueling process.

You had scientists in lab coats hunched over microscopes, trying to figure out which molecules might, just might, be the magic bullet for some disease.

It took years, sometimes decades, and billions of dollars.

And even then, more than half of those drugs didn’t make it past the first phase of trials.

But now, AI is stepping into the ring…

The AI Drug Rush

And it’s not just frolicking in the fringes—it’s beginning to dominate. The mainstream media isn’t reporting on it, but it’s happening.

We’re talking about a leap from a 63% success rate in Phase 1 trials to a mind-blowing 80-90% success rate.

Our colleague Ray Blanco calls it the “AI Drug Rush.”

And this is the kind of rush that only comes around once in a generation.

Our main beat here in ALC: It pays to be optimistic.

Just Call It The Nvidia Show

Posted January 09, 2026

By Chris Campbell

Different booths. Different demos. Same vibe. Just call it The Nvidia Show.

CES: Things Get Physical in Vegas

Posted January 08, 2026

By Chris Campbell

When intelligence leaves the screen, the connective tissue starts to matter as much as the brain.

The Personal AI Revolution

Posted January 07, 2026

By Chris Campbell

No one wants their grandchildren growing up inside a single, approved version of reality. Here’s the solution.

Venezuela Beyond the Headlines

Posted January 06, 2026

By Chris Campbell

Here’s how to think about Venezuela the way a hedge fund would (and is).

5 Bets for a World That Won’t Behave

Posted January 05, 2026

By Chris Campbell

We’ll return to this later to see whether this portfolio was prescient, premature, or best recalled with a stiff drink in hand.

The Anti-Capsule Portfolio For 2026

Posted January 02, 2026

By Chris Campbell

It doesn’t look tidy. It’s not very photogenic. But it’s a good way to think about a world under stress.